Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Leases: 2019-2024

Historic Current Leases for Cartesian Therapeutics (RNAC) over the last 6 years, with Dec 2024 value amounting to $2.9 million.

  • Cartesian Therapeutics' Current Leases rose 39.93% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 39.93%. This contributed to the annual value of $2.9 million for FY2024, which is 31.63% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Current Leases is $2.9 million, which was up 31.63% from $2.2 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Current Leases registered a high of $2.9 million during FY2024, and its lowest value of $908,000 during FY2020.
  • In the last 3 years, Cartesian Therapeutics' Current Leases had a median value of $2.2 million in 2023 and averaged $2.2 million.
  • Data for Cartesian Therapeutics' Current Leases shows a peak YoY soared of 144.09% (in 2020) over the last 5 years.
  • Cartesian Therapeutics' Current Leases (Yearly) stood at $908,000 in 2020, then rose by 15.53% to $1.0 million in 2021, then surged by 53.29% to $1.6 million in 2022, then surged by 34.70% to $2.2 million in 2023, then soared by 31.63% to $2.9 million in 2024.